Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer
Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer
复制标题
DOI：
10.1093/annonc/mdg413
复制
发表时间：
2003-10-01
影响因子：
50.5
通讯作者：
Lichtenegger, W
中科院分区：
文献类型：
--
作者：
Sehouli, J;Mustea, A;Lichtenegger, W
背景：不同的研究表明，免疫成分在癌症的发生发展中起着关键作用。白介素1(IL-1)被认为与卵巢癌和其他实体肿瘤的发生密切相关。因此，我们探讨了白细胞介素1受体拮抗剂(IL-1RA)基因多态性对卵巢癌发生发展的可能影响。结果：研究组和对照组等位基因1/2杂合子的频率分布差异有统计学意义(32.4%vs15.2%；P=0.004)。IL-1RA(IL-RA1/2)等位基因2杂合者患卵巢癌的风险显著增加，其优势比为2.7(95%可信区间1.4~5.2)。IL-1RA基因1/2多态与肿瘤分期(国际妇产科联合会)、组织类型、分级、术后肿瘤体积、腹水量、复发情况、年龄无明显差异。结论：IL-1RA基因等位基因2多态可能与卵巢癌的发生有关，应作为卵巢癌筛查和危险性评估的参考指标。
Background: Different studies indicate that immunological components play a key role in the development of cancer. Interleukin-1 (IL-1) is known to be critically involved in ovarian carcinogenesis and in other solid tumors. Therefore, we investigated the possible influence of the polymorphism of the IL-1 receptor antagonist (IL-1 RA) genes on the development of ovarian cancer.Patients and methods: In a prospective study we analyzed the polymorphism of the IL-1 RA gene in 108 women with ovarian cancer compared with 112 patients with benign gynecological diseases. Genomic DNA fragments were amplified by PCR.Results: The distribution of genotype frequencies was significantly different between the study and control group with respect to allele 1/2 heterozygotes (32.4% versus 15.2%; P = 0.004). Patients who were heterozygous at allele 2 for IL-1 RA (IL-RA 1/2) had a significantly higher risk of ovarian cancer with a calculated odds ratio of 2.7 (95% confidence interval 1.4-5.2). There were no differences between IL-1 RA 1/2 polymorphism and all other alleles in tumor stage (International Federation of Gynecology and Obstetrics), histological type, grading, postoperative tumor volume, volume of ascites, recurrence status or age.Conclusions: The allele 2 polymorphism of the IL-1 RA gene seems to play a role in the occurrence of ovarian cancer and should be investigated for screening and risk evaluation.